Effects of high-dose vitamin D supplementation in patients with multiple sclerosis: A systematic review of efficacy and safety
Ghamdi KA, Alqarni M, Alamri Z, Wahhas MA, Alkhaldi M, Alsanni A, Alhawaj AF
Multiple sclerosis and related disorders · 0 citas
Etiquetas de revisión
Financiación no declaradaDatos neutrales que nuestra revisión registró sobre cómo se hizo este estudio. Describen el método, nunca si nos gusta el resultado.
Cómo se estudió
- Diseño
- Revisión sistemática (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
Quién lo pagó
- Financiación
- Financiación no declarada
Publicación
- Publicado
- 2026-06-14 · Mult Scler Relat Disord · vol. 112 · pág. 107324
- Editorial
- Elsevier BV
- Citado
- 0 citas · más que el 36% de estudios similares · 0.0× el promedio de su campo
- Referencias
- 23 trabajos
- Acceso
- Acceso abierto (revista híbrida) · CC-BY
- Áreas de investigación
- Multiple Sclerosis Research Studies · Vitamin D Research Studies · Psoriasis: Treatment and Pathogenesis
- Palabras clave
- multiple sclerosis, high-dose vitamin D supplementation, vitamin D, immunomodulation, disability progression, MRI lesion activity, IL-17, serum 25-hydroxyvitamin D, serum calcium, adverse events, adjunctive therapy
- MeSH
- humans, multiple sclerosis, vitamins, vitamin d, dietary supplements
7 autores
- Kholoud S. Al Ghamdi🇸🇦 · autor de correspondenciaImam Abdulrahman Bin Faisal University
- Mohammed Abdullah Alqarni🇸🇦Imam Abdulrahman Bin Faisal University
- Ziyad Alamri🇸🇦Imam Abdulrahman Bin Faisal University
- Mohand AL Wahhas🇸🇦Imam Abdulrahman Bin Faisal University
- Muhammad Alkhaldi🇸🇦Imam Abdulrahman Bin Faisal University
- Abdulrahman Alsanni🇸🇦Imam Abdulrahman Bin Faisal University
- Ali Fouad Alhawaj🇸🇦Imam Abdulrahman Bin Faisal University
Resumen
El texto original del estudio, en el idioma en que se publicó.
Background
Multiple sclerosis (MS), a chronic autoimmune disease, is the leading cause of non-traumatic neurological disability in young adults. Vitamin D plays a vital immunomodulatory role, and deficiency has been linked to increased MS risk and activity. High-dose vitamin D supplementation has been proposed as a therapeutic approach. However, safety concerns and inconsistent evidence on efficacy highlights the need for systematic evaluation.
Objectives
To evaluate the efficacy and safety of high-dose vitamin D supplementation in patients with MS, with emphasis on immune markers, disability progression, magnetic resonance imaging (MRI) findings, and reported adverse-events.
Methods
This systematic review follows the PRISMA 2020 guidelines. The protocol was registered on PROSPERO (CRD420251128444). Relevant studies were systematically retrieved and searched in public databases. Randomized controlled trials were included that evaluates high-dose vitamin D supplementation (≥10,000 IU/day) in adults with multiple sclerosis, reporting efficacy and/or safety. Data extraction was performed independently by two reviewers. Risk of bias was assessed using RoB-2 for randomized trials. Outcomes of interest are safety, MRI findings, clinical measures, and immunological biomarkers.
Results
Eleven randomized controlled trials were included. High-dose vitamin D increased serum 25‑hydroxy vitamin D levels and was surprisingly safe, with rare and transient disturbances in calcium serum levels. MRI and clinical outcomes showed variable effects. Several trials demonstrated immunomodulatory effects, particularly reductions in interleukin-17-related pro-inflammatory activity.
Conclusion
High-dose vitamin D is safe under appropriate monitoring. While clinical and radiological benefits remain inconsistent, evidence of immune modulation suggests a promising adjunctive role requiring further investigation in larger, long-term trials.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial (CC BY).
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.